Alembic Pharmaceuticals Limited
NSE: APLLTD BSE: APLLTD
NSE
1,007.40
18.90 (1.91%)
Prev Close
988.5
Open Price
998.9
Volume
422,346
Today Low / High
980.2 / 1012.9
52 WK Low / High
725.2 / 1303.9
Range
957 - 1,058
BSE
1,008.40
18.75 (1.89%)
Prev Close
989.65
Open Price
999.05
Volume
35,983
Today Low / High
980 / 1012.05
52 WK Low / High
725.6 / 1296.15
Range
958 - 1,059
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1007.4 (target range: 957 - 1,058), reflecting a change of 18.9 (1.91199%). On the BSE, it is listed at 1008.4 (target range: 958 - 1,059), showing a change of 18.75 (1.89461%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
02 Jul
1,009.90
-1.68%
01 Jul
1,024.80
-1.24%
30 Jun
989.00
5.07%
27 Jun
969.00
-0.01%
26 Jun
977.00
-0.25%
25 Jun
946.90
2.64%
24 Jun
942.30
0.49%
23 Jun
940.10
-0.05%
20 Jun
929.60
0.55%
19 Jun
954.90
-2.28%
18 Jun
969.00
-1.05%
17 Jun
968.30
0.09%
16 Jun
999.00
-2.80%
13 Jun
986.70
1.26%
12 Jun
1,005.50
-1.28%
11 Jun
988.90
0.75%
10 Jun
991.50
-0.89%
09 Jun
987.40
0.24%
06 Jun
980.80
0.69%
Alembic Pharmaceuticals Limited Graph
Alembic Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alembic Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,007.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,008.40 | 1,018.48 | 916.64 - 1,120.33 |
| 1,028.57 | 822.85 - 1,234.28 | ||
| 1,038.65 | 727.06 - 1,350.25 | ||
| Bearish Scenario | 1,008.40 | 998.32 | 898.48 - 1,098.15 |
| 988.23 | 790.59 - 1,185.88 | ||
| 978.15 | 684.70 - 1,271.59 |
Overview of Alembic Pharmaceuticals Limited
ISIN
INE901L01018
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
446,630
Market Cap
195,167,402,700
Last Dividend
11
Official Website
IPO Date
2011-09-20
DCF Diff
222.29
DCF
790
Financial Ratios Every Investor Needs
Stock Dividend of APLLTD
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-29 | July 29, 25 | 11 | 11 | 2025-07-29 | 2025-09-04 | |
| 2024-07-15 | July 15, 24 | 11 | 11 | 2024-07-15 | 2024-08-21 | |
| 2023-07-28 | July 28, 23 | 8 | 8 | 2023-07-28 | 2023-09-03 | |
| 2022-08-17 | August 17, 22 | 10 | 10 | 2022-08-18 | 2022-09-03 | |
| 2021-07-19 | July 19, 21 | 14 | 14 | 2021-07-20 | 2021-07-31 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 6,672.08 Cr | 1,793.36 Cr | 4,878.72 Cr | 0.7312 | 0.00 Cr | 0.00 Cr | 3,316.38 Cr | 583.42 Cr | 29.68 | 1,008.23 Cr | 0.0874 |
| 2024-03-31 | 6,228.63 Cr | 3,959.80 Cr | 2,268.83 Cr | 0.3643 | 438.56 Cr | 251.97 Cr | 575.81 Cr | 615.82 Cr | 31.33 | 961.67 Cr | 0.0989 |
| 2023-03-31 | 5,652.62 Cr | 1,708.82 Cr | 3,943.80 Cr | 0.6977 | 29.07 Cr | 241.05 Cr | 437.78 Cr | 341.99 Cr | 17.40 | 711.11 Cr | 0.0605 |
| 2022-03-31 | 5,231.79 Cr | 1,723.19 Cr | 3,508.60 Cr | 0.6706 | 50.59 Cr | 210.98 Cr | 587.47 Cr | 520.94 Cr | 26.50 | 924.62 Cr | 0.0996 |
| 2021-03-31 | 5,276.22 Cr | 1,521.27 Cr | 3,754.95 Cr | 0.7117 | 25.38 Cr | 208.66 Cr | 1,296.84 Cr | 1,146.50 Cr | 59.18 | 1,567.57 Cr | 0.2173 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 90.10 Cr | 7,772.94 Cr | 2,583.42 Cr | 5,190.9400 Cr | 1,257.50 Cr | 1,167.40 Cr | 2,288.14 Cr | 3,360.76 Cr | 0.00 Cr | 0.00 Cr | 127.21 Cr | 2,412.3300 Cr |
| 2024-03-31 | 120.21 Cr | 6,445.58 Cr | 1,627.38 Cr | 4,818.2000 Cr | 513.16 Cr | 392.95 Cr | 1,643.54 Cr | 3,071.05 Cr | 0.00 Cr | 0.00 Cr | 93.02 Cr | 1,455.0000 Cr |
| 2023-03-31 | 75.48 Cr | 6,182.83 Cr | 1,812.36 Cr | 4,370.4700 Cr | 722.02 Cr | 646.54 Cr | 1,475.27 Cr | 2,999.73 Cr | 218.79 Cr | -83.14 Cr | 96.33 Cr | 1,636.9300 Cr |
| 2022-03-31 | 61.09 Cr | 7,122.03 Cr | 1,884.48 Cr | 5,237.5500 Cr | 717.11 Cr | 656.02 Cr | 1,609.70 Cr | 3,947.26 Cr | 365.18 Cr | -197.69 Cr | 118.40 Cr | 1,716.5300 Cr |
| 2021-03-31 | 98.06 Cr | 6,708.98 Cr | 1,642.01 Cr | 5,127.6100 Cr | 583.61 Cr | 485.55 Cr | 1,486.15 Cr | 3,648.03 Cr | 299.87 Cr | 85.52 Cr | 49.31 Cr | 1,280.8400 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 87.9700 Cr | -568.4100 Cr | 443.7100 Cr | -475.6500 Cr | -36.7300 Cr | 83.4800 Cr | -563.6200 Cr | 583.4200 Cr | -26.5600 Cr | -216.2200 Cr | -644.6000 Cr |
| 2024-03-31 | 803.2000 Cr | -320.6100 Cr | -437.8700 Cr | 475.7300 Cr | 44.7300 Cr | 120.2100 Cr | -327.4700 Cr | 615.8200 Cr | -205.4100 Cr | -157.2500 Cr | -168.2800 Cr |
| 2023-03-31 | 723.9500 Cr | -447.5900 Cr | -261.9600 Cr | 280.5400 Cr | 14.3900 Cr | 75.4800 Cr | -443.4100 Cr | 354.5900 Cr | 5.8700 Cr | -196.5600 Cr | 134.4400 Cr |
| 2022-03-31 | 552.3500 Cr | -371.9700 Cr | -217.3500 Cr | 126.7100 Cr | -36.9700 Cr | 61.0900 Cr | -425.6400 Cr | 620.1100 Cr | 129.9800 Cr | -275.1900 Cr | -123.5500 Cr |
| 2021-03-31 | 1,463.3800 Cr | -838.8100 Cr | -597.4300 Cr | 803.8700 Cr | 26.2200 Cr | 98.0600 Cr | -659.5100 Cr | 1,368.0800 Cr | -397.9900 Cr | 0.0000 Cr | -298.6200 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,769.64 Cr | 530.61 Cr | 1,239.03 Cr | 0.7002 | 845.44 Cr | 156.89 Cr | 7.98 | 272.59 Cr | 0.0887 |
| 2024-12-31 | 1,692.74 Cr | 439.54 Cr | 1,253.20 Cr | 0.7403 | 190.18 Cr | 138.42 Cr | 7.01 | 270.08 Cr | 0.0818 |
| 2024-09-30 | 1,647.98 Cr | 429.12 Cr | 1,218.86 Cr | 0.7396 | 168.75 Cr | 153.41 Cr | 7.79 | 269.74 Cr | 0.0931 |
| 2024-06-30 | 1,561.73 Cr | 842.90 Cr | 718.83 Cr | 0.4603 | 167.79 Cr | 134.71 Cr | 6.84 | 238.93 Cr | 0.0863 |
| 2024-03-31 | 1,516.98 Cr | 850.70 Cr | 666.28 Cr | 0.4392 | 190.58 Cr | 178.21 Cr | 9.07 | 263.66 Cr | 0.1175 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 90.10 Cr | 0.00 Cr | 90.10 Cr | 1,399.79 Cr | 2,288.14 Cr | 4,087.80 Cr | 3,360.76 Cr | 7,772.94 Cr | 2,583.42 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 128.95 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -4,887.64 Cr |
| 2024-09-30 | 122.05 Cr | 27.22 Cr | 149.27 Cr | 0.00 Cr | 2,012.52 Cr | 3,762.39 Cr | 3,124.86 Cr | 7,230.25 Cr | 2,342.61 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 120.21 Cr | 0.00 Cr | 0.00 Cr | 120.21 Cr | 0.00 Cr | 0.00 Cr | -4,818.20 Cr |
| 2024-03-31 | 126.57 Cr | 27.13 Cr | 126.57 Cr | 1,024.84 Cr | 1,643.54 Cr | 3,078.56 Cr | 3,071.07 Cr | 6,445.58 Cr | 1,627.38 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 156.89 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 138.42 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 153.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 134.71 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 178.21 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.70 | ₹4,030,070,616,000.00 | ₹1,553,567.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,876.00 | ₹1,825,364,844,000.00 | ₹302,963.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,334.10 | ₹1,128,409,474,500.00 | ₹521,114.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,291.30 | ₹1,074,464,568,262.00 | ₹1,918,881.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹999.40 | ₹1,005,626,262,000.00 | ₹718,016.00 |
| Mankind Pharma Limited | MANKIND | ₹2,361.70 | ₹974,741,512,492.00 | ₹237,139.00 |
| Lupin Limited | LUPIN | ₹1,954.80 | ₹892,747,386,000.00 | ₹739,836.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,156.10 | ₹671,465,192,200.00 | ₹1,234,267.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,822.00 | ₹576,542,430,000.00 | ₹191,371.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,783.50 | ₹503,305,483,500.00 | ₹442,217.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Laurus Labs Limited | LAURUSLABS | ₹758.55 | ₹409,050,363,150.00 | ₹2,481,595.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,007.40 | ₹385,398,003,859.00 | ₹394,907.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,415.70 | ₹359,168,752,800.00 | ₹386,552.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,631.50 | ₹328,705,928,000.00 | ₹166,019.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,748.40 | ₹284,078,283,600.00 | ₹860,413.00 |
| Piramal Enterprises Limited | PEL | ₹1,162.50 | ₹263,513,175,000.00 | ₹265,665.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,639.40 | ₹255,843,124,600.00 | ₹434,522.00 |
| Eris Lifesciences Limited | ERIS | ₹1,718.60 | ₹234,068,164,200.00 | ₹458,154.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,111.50 | ₹227,787,500,000.00 | ₹48,141.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹1,007.40 | ₹198,017,566,200.00 | ₹422,346.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,201.50 | ₹191,376,121,500.00 | ₹217,034.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹973.60 | ₹174,381,496,000.00 | ₹5,924,165.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,002.40 | ₹152,205,828,080.00 | ₹67,104.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹11,668.00 | ₹149,699,273,200.00 | ₹89,171.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹490.15 | ₹118,931,956,600.00 | ₹447,075.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,854.00 | ₹97,172,887,600.00 | ₹2,998.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹890.35 | ₹87,068,127,815.00 | ₹64,974.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹904.45 | ₹81,974,482,059.00 | ₹243,719.00 |
| Strides Pharma Science Limited | STAR | ₹883.75 | ₹81,448,786,125.00 | ₹525,530.00 |
| FDC Limited | FDC | ₹486.65 | ₹79,231,486,500.00 | ₹56,696.00 |
| Suven Life Sciences Limited | SUVEN | ₹247.96 | ₹54,073,629,040.00 | ₹93,229.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹159.30 | ₹51,696,354,600.00 | ₹272,441.00 |
| Innova Captab Limited | INNOVACAP | ₹856.10 | ₹48,990,262,573.00 | ₹41,384.00 |
| Sequent Scientific Limited | SEQUENT | ₹185.89 | ₹46,529,196,450.00 | ₹294,573.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹483.90 | ₹44,165,553,000.00 | ₹340,477.00 |
| Hikal Limited | HIKAL | ₹347.30 | ₹42,822,437,300.00 | ₹229,858.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,502.30 | ₹41,385,539,700.00 | ₹14,803.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹584.20 | ₹41,131,068,360.00 | ₹23,214.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹747.55 | ₹37,915,063,205.00 | ₹190,198.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹63.94 | ₹35,036,178,760.00 | ₹8,223,557.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹348.90 | ₹34,986,994,200.00 | ₹37,031.00 |
| Indoco Remedies Limited | INDOCO | ₹338.80 | ₹31,253,588,520.00 | ₹140,771.00 |
| Alembic Limited | ALEMBICLTD | ₹119.39 | ₹30,657,202,861.00 | ₹607,232.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹636.65 | ₹30,656,607,450.00 | ₹79,206.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹93.41 | ₹27,418,357,070.00 | ₹726,705.00 |
Key Executives
MD & Executive Director
Mr. Shaunak Chirayu Amin
Gender: male
Year Born: 1978
Director of Finance, Chief Financial Officer & Executive Director
Mr. Raj Kumar Shreeram Baheti B.Com.(Hon.), FCA, FCS
Gender: male
Year Born: 1959
Chief Scientific Officer
Dr. J. Venkat Raman M. S., Ph.D.
Gender: Not Specified
Year Born: 1958
Company Secretary & Compliance Officer
Ms. Manisha Saraf
Gender: female
Year Born:
Managing Director
Mr. Pranav Chirayu Amin
Gender: male
Year Born: 1975
Head of Technical Operations
Mr. Sudhakar Pandiyan
Gender: male
Year Born:
Chief Business Development Officer
Mr. Udit C. Amin
Gender: male
Year Born: 1980
Senior Vice President
Mr. Gautam Chatterjee
Gender: male
Year Born: 1961
Executive Chairman & Chief Executive Officer
Mr. Chirayu Ramanbhai Amin
Gender: male
Year Born: 1946
Senior Vice President of Finance
Mr. Ajay Kumar Desai
Gender: male
Year Born:
FAQs about Alembic Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Chirayu Ramanbhai Amin.
What is the current market price of the stock?
The current price is ₹992.90.
What is the 52-week price range?
The range is ₹725.2-1303.9.
What is the market capitalization of the company?
The market capitalization is ₹19,516.74 crores.
What is the dividend yield?
The dividend yield is 1.11%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 33.46.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Alembic Pharmaceuticals Limited (ISIN: INE901L01018) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹19,516.74 crores and an average daily volume of 446,630 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹11.